CompletedPhase 1

Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

United States5 participantsStarted 2018-08-23

Plain-language summary

This research study is studying a drug as a possible treatment for BPDCN. The intervention involved in this study is: Venetoclax

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Dose Limiting Toxicity

Timeframe: 2 years

NCT IDNCT03485547

SponsorDana-Farber Cancer Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-01-10